Discussion

Enumeration of CTCs at baseline in NSCLC and SCLC provide prognostic information. In this presentation I will describe our current efforts to exploit CTCs to develop predictive biomarkers for personalised therapy, to discover more about the biology of metastasis, to reveal novel drug targets and to use CTCs to monitor the emergence of resistance to targeted therapies.
I will also describe the development of unique CTC derived mouse models that provide us with new opportunities to understand the biology SCLC, a disease where serial tumour biopsy is rarely obtained.